JNM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Figures Only
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Related articles in JNM
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Raffel, D. M.
Right arrow Articles by Gilman, S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Raffel, D. M.
Right arrow Articles by Gilman, S.
Journal of Nuclear Medicine Vol. 47 No. 11 1769-1777
© 2006 by Society of Nuclear Medicine


Clinical Investigation

PET Measurement of Cardiac and Nigrostriatal Denervation in Parkinsonian Syndromes

David M. Raffel1, Robert A. Koeppe1, Roderick Little2, Chia-Ning Wang2, Suyu Liu2, Larry Junck3, Mary Heumann3 and Sid Gilman3

1 Division of Nuclear Medicine, Department of Radiology, University of Michigan, Ann Arbor, Michigan; 2 Department of Biostatistics, University of Michigan, Ann Arbor, Michigan; and 3 Department of Neurology, University of Michigan, Ann Arbor, Michigan

Correspondence: For correspondence or reprints contact: David M. Raffel, PhD, Division of Nuclear Medicine, Department of Radiology, University of Michigan Medical School, 3480 Kresge III Bldg., Ann Arbor, MI 48109-0552. E-mail: raffel{at}umich.edu

Scintigraphic imaging with 123I-metaiodobenzylguanidine (123I-MIBG) has demonstrated extensive losses of cardiac sympathetic neurons in idiopathic Parkinson's disease (IPD). In contrast, normal cardiac innervation has been observed in 123I-MIBG studies of multiple-system atrophy (MSA) and progressive supranuclear palsy (PSP). Consequently, it has been hypothesized that cardiac denervation can be used to differentiate IPD from MSA and PSP. We sought to test this hypothesis by mapping the distribution of cardiac sympathetic neurons in patients with IPD, MSA, and PSP by using PET and 11C-meta-hydroxyephedrine (11C-HED). Also, the relationship between cardiac denervation and nigrostriatal denervation was investigated by measuring striatal presynaptic monoaminergic nerve density with PET and 11C-dihydrotetrabenazine (11C-DTBZ). Methods: 11C-HED and 11C-DTBZ scans were obtained for patients with IPD (n = 9), MSA (n = 10), and PSP (n = 8) and for age-matched control subjects (n = 10). Global and regional measurements of 11C-HED retention were obtained to assess the extent of cardiac sympathetic denervation. 11C-DTBZ binding was measured in the caudate nucleus, anterior putamen, and posterior putamen. Results: As expected, extensive cardiac denervation was observed in several of the patients with IPD. However, substantial cardiac denervation was also seen in some patients with MSA and PSP. 11C-DTBZ studies demonstrated striatal denervation in all patients with IPD and in most patients with MSA and PSP. No correlation was found between cardiac 11C-HED retention and striatal 11C-DTBZ binding. Conclusion: Cardiac sympathetic denervation was found to occur not only in IPD but also in other movement disorders, such as MSA and PSP. This finding implies that scintigraphic detection of cardiac sympathetic denervation cannot be used independently to discriminate IPD from other movement disorders, such as MSA and PSP. Cardiac sympathetic denervation was not correlated with striatal denervation, suggesting that the pathophysiologic processes underlying cardiac denervation and striatal denervation occur independently in patients with parkinsonian syndromes. These findings provide novel information about central and peripheral denervation in patients with neurodegenerative disorders.

Key Words: Parkinson's disease • multiple-system atrophy • progressive supranuclear palsy • PET • meta-hydroxyephedrine • dihydrotetrabenazine


Related articles in JNM:

This Month in JNM

JNM 2006 47: 9a-10a. [Full Text]  



This article has been cited by other articles:


Home page
NeurologyHome page
S. Gilman, G. K. Wenning, P. A. Low, D. J. Brooks, C. J. Mathias, J. Q. Trojanowski, N. W. Wood, C. Colosimo, A. Durr, C. J. Fowler, et al.
Second consensus statement on the diagnosis of multiple system atrophy
Neurology, August 26, 2008; 71(9): 670 - 676.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
JOURNAL OF NUCLEAR MEDICINE TECHNOLOGY THE JOURNAL OF NUCLEAR MEDICINE
Copyright © 2006 by the Society of Nuclear Medicine.